- Home
- Companies
- afghanistan
- disease progression
Show results for
Refine by
Disease Progression Suppliers Serving Afghanistan
89 companies found
based inFranklin Lakes, NEW JERSEY (USA)
BD is a global medical technology company that is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. BD leads in patient and healthcare worker safety and the technologies that enable medical research ...
based in
Tectonic Therapeutic, Inc., a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs, announced merger with AVROBIO, Inc. The combined company will ...
based inPlanegg, GERMANY
MorphoSys is a commercial-stage biopharmaceutical company dedicated to the discovery, development, and delivery of innovative cancer medicines. At MorphoSys, our ambition is to redefine how cancer is treated. As a commercial-stage biopharmaceutical ...
Pelabresib (CPI-0610) is an investigational selective small-molecule designed to promote anti-tumor activity by inhibiting the function of bromodomain and extra-terminal domain (BET) proteins to decrease the expression of abnormally expressed genes ...
based inGuildford, UNITED KINGDOM
Datar Cancer Genetics is a leader in developing blood-based diagnostics that can detect cancer early, offer non-invasive investigations for better treatment options, and track the progression of the disease or its recurrence. We believe that ...
Cancertrack is an advanced non-invasive blood test which provides real time intel on the status of a malignancy from a safe, simple and quick blood draw. Cancertrack profiles molecular features in circulating tumor DNA and circulating tumor RNA and ...
based inGuangzhou, CHINA
Guangzhou Wondfo Biotech Co., Ltd., headquartered in Guangzhou science city, has been focusing on the R&D, production, sales and service of point-of-care testing (POCT) products and providing customers with professional rapid diagnosis and chronic ...
RBD (receptor binding domain) of 2019-nCoV virus S1 protein is the region that binds to the ACE2 receptor on human cells as the first step of virus invading. The majority and most potency neutralizing antibody targets the epitopes on RBD, therefore ...
based inAmsterdam, NETHERLANDS
Self-screen has a long history and track record in translational HPV related science. The company was founded in 2008 to advance the implementation of scientific discoveries in the field of HPV related cancer screening into routine practice. Our ...
based inMechelen, BELGIUM
Galapagos discovers, develops and commercializes small molecule medicines with novel modes of action. Our pipeline comprises discovery through to Phase 3 programs in inflammation, fibrosis, and other indications. Our first medicine is approved and ...
based inFlorence, ITALY
The Menarini Group is a leading international pharmaceutical and diagnostics company, with a turnover of over $4 billion and over 17,000 employees. Menarini is focused on therapeutic areas with high unmet needs with products for cardiology, ...
Elacestrant is a selective estrogen receptor degrader (SERD) evaluated for potential use as a once daily oral treatment in patients with estrogen receptor positive (ER+)/HER2- advanced or metastatic breast cancer. Studies completed to date, ...
based inSydney, AUSTRALIA
Uscom Limited (UCM) is an Australian founded, ASX listed innovative medical technology company specialising in development and global marketing of premium non-invasive cardiovascular and pulmonary medical devices. Uscom has a mission to demonstrate ...
The SpiroSonic Ultrasonic spirometer employs advanced multi-path ultrasound technology to deliver high-fidelity pulmonary function ...
based inWürzburg, GERMANY
Toleris Biotherapeutics GmbH is a biotechnology company based in Würzburg, Germany. The company specializes in the development of innovative biotherapeutic solutions aiming to advance the field of medicine through cutting-edge scientific research. ...
By leveraging optimized soluble versions of the non-classical MHC Ib molecule HLA-G, AIM Biologicals can accumulate in lymph nodes to induce regulatory CD8+ T cells that protect tissues presenting autoantigens attacked in autoimmune ...
based inWest Lafayette, INDIANA (USA)
Tymora Analytical Operations provides diagnostic development and exosome proteomics contract services and products for improved cancer research. Tymora’s primary goal is to enable the shift from tissue to liquid biopsy. Our new technologies allow ...
based inFramingham, MASSACHUSETTS (USA)
Kephera Diagnostics is a startup that aims to address the public health challenges of global infectious diseases with point of care assay technology. We collaborate with a global community of researchers to develop and translate new technologies ...
Kephera is developing a new test for Lyme disease, supported by a grant from the National Institute of Allergy and Infectious Diseases. Lyme disease has become the most common vector-borne disease in the U.S., with over 300,000 cases per year ...
based inCambridge, MASSACHUSETTS (USA)
The exponential growth of biomedical data, driven by the adoption of electronic medical records (EMRs), provides an unprecedented opportunity to create transformative technologies and products in healthcare. nference partners with medical centers to ...
Our scientists use the nference platform and data in collaboration with your teams to tackle your most important questions and challenges. nference is creating the largest labeled EMR dataset in healthcare. EMR data contains longitudinal real-world, ...
based inTel Aviv, ISRAEL
The volume of human molecular data is growing exponentially, but our analytic capabilities are growing linearly, at best. Humans alone cannot process all this data. What’s needed is a technology capable of digesting, organizing and making sense of ...
The first model to map and compare treatments, patient groups and disease mechanisms. ...
based inCopenhagen, DENMARK
Cmbio specializes in advancements in microbiome science and multi-omics research, primarily focused on human, animal, and planetary health. With a team of over 100 experts in microbiology, bioinformatics, metabolomics, molecular biology, and data ...
based inClichy, FRANCE
CorWave is a fast-paced medical device company that develops innovative heart-assist pumps to bring a reliable and sustainable solution to heart failure, a major public health challenge. The truly physiological solutions developed by CorWave aim to ...
Nemo is an implantable, minimally invasive cardiac pump designed to provide chronic, partial support to heart failure patients who are not eligible for LVADs and for whom there is currently no adequate ...
based inNewark, CALIFORNIA (USA)
ACD - a Bio-Techne brand, shortens the path to personalized medicine and enables research, drug development and clinical applications by unlocking the power of RNA. ACD is a leader in the emerging field of molecular pathology, developing cell- and ...
ACD's Professional Assay Services group has been developing RNAscope™ biomarker assays for our biopharma partners for a decade. Our biomarker assays have contributed to important clinical trial exploratory endpoints, enabled more accurate ...
based inLondon, UNITED KINGDOM
ReGen (Therapeutics Plc) was formed in February 1998 to develop Colostrinin™, a proline-rich polypeptide complex derived from mammalian colostrum. Colostrinin™ is promoted as having utility as a support for healthy brain ageing and cognition. ...
based inBoston, MASSACHUSETTS (USA)
Accelerating Discovery in CNS, Cardiometabolic and Inflammatory Disease. We support our clients to achieve more in their target & biomarker programs. Our expertise, curated & disease enriched clinco-omic cohorts, tools and applications for insight ...
We are developing novel causal artificial intelligence and machine learning (AI/ML) and unconventional computing strategies to better understand human biology – and then apply these to deliver better medicine and improve health for people ...
based inOxford, UNITED KINGDOM
Evox Therapeutics is a privately held, Oxford-based biotechnology company focused on improving the natural delivery capabilities of exosomes, and developing an entirely new class of therapeutics. Backed by leading venture capital groups and ...